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The S ‑ICD implantation procedure was per‑
formed under general anesthesia. In the first 3 
cases, the S ‑ICD pocket was subcutaneous, an in 
the remaining cases, intermuscular. In 21 pa‑
tients, the defibrillation test was performed, and 
in 4 patients, it was abandoned due to contrain‑
dications (see Supplementary material, Table S1).
Only descriptive statistical methods were used.
Due to observational nature of the study, no 
additional patient consent was required.
Results and discussion No perioperative com‑
plications were observed.
Out of 21 patients in whom the defibrillation 
test was performed, in 20 cases, the first 65‑J 
shock was effective. In one patient, the shock 
polarity inversion was required to achieve ter‑
mination of ventricular fibrillation.
No late surgical complications were observed 
during the follow ‑up.
Subcutaneous implantable cardioverter ‑defibril‑
lator interventions An adequate antiarrhyth‑
mic intervention of S ‑ICD was observed in one 
patient (4%, patient number 9). Ventricular ar‑
rhythmias occurred 5 times and they were ter‑
minated by the first 80‑J shock. The patient died 
9 months following the implantation due to pro‑
gressive heart failure and pneumonia.
Inadequate interventions were observed in 
5 patients (20%). In 2 cases (8%), they were re‑
lated to atrial fibrillation (AF), in 1 case (4%) 
to an interaction between S ‑ICD and pacemak‑
er, and in the remaining 2 cases (8%), the exact 
Introduction A totally subcutaneous implant‑
able cardioverter ‑defibrillator (S ‑ICD) is an es‑
tablished method of treatment in patients at risk 
for sudden cardiac death (SCD). Both the Amer‑
ican and European guidelines recommend its 
application as a class IIa recommendation, in 
case of indications for implantable cardioverter‑
‑defibrillator in patients who do not require per‑
manent cardiac pacing or antitachycardia pac‑
ing.1 The high cost of the device and limited re‑
imbursement result in a relatively small num‑
ber of patients treated with S ‑ICD and centers 
using that method in Poland. In this study we 
present the 5‑year single ‑center experience with 
the use of S ‑ICD.
Methods The study group included 25 patients 
(13 women and 12 men) at the mean (SD) age of 
49 (17) years (range, 13–70 years). One patient 
(number 1) had his device implanted abroad, and 
he underwent a pocket repair procedure in our 
center. The S ‑ICD was implanted for secondary 
prevention of SCD in 18 patients. The decision 
to choose S ‑ICD was based on additional clini‑
cal factors, and in many cases multiple factors 
were present (obstructed vascular access in 9 
patients, high risk for infective complications 
in 6, young age in 8, and a history of failures 
of transvenous leads in 7; 1 indication in 9 pa‑
tients [36%], 2 in 10 patients [40%], 3 in 4 pa‑
tients [16%], 4 in 1 patient [4%], and 5 in 1 pa‑
tient [4%]). Left ventricular ejection fraction 
was 15% to 66% (mean [SD], 48% [15%]). De‑
tailed data are presented in TABLE 1.
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448 TABLE 1 Clinical and demographic data of the study group
Patient 
no.












Prior CIED Prior extraction 
of CIED







1 M 40 I 65 SR IVF Secondary No No No No 3 68
2 F 57 I 60 SR IVF Secondary No No No No 1, 2 61
3 F 62 I 30 SR ICM Primary No No No No 1, 2 56
4 F 34 I 50 SR ARVC Primary ICD VR Yes No No 1, 2, 3, 4, 5 48
5 M 70 II 40 SR ICM Secondary Epicardial VVI No Epicardial VVI Paroxysmal AVB III 2 41
6 M 39 I 60 SR HCM Primary DDD No DDD (both leads inactive) No 1, 3 38
7 F 60 I 55 SR IVF Secondary ICD VR Yes (only device can) No (only abandoned lead) No 1 36
8 M 60 I 35 AF NICM Secondary ICD VR Yes ICD VR No 1, 6 35
9 F 63 II 25 AF LVNC Secondary ICD VR Yes No No 2, 4, 5 9
10 F 68 I 30 SR ICM Primary ICD VR Yes ICD ‑VR No 1, 6 32
11 M 65 II 35 SR ICM Secondary ICD VR Yes ICD ‑VR No 1, 6 30
12 F 69 I 50 SR IVF Secondary No No No No 2 29
13 M 16 III 15 SR NICM Primary DDD No DDD LBBB, AVB I/II/III 1, 3 2 (followed by heart transplant)
14 F 59 I 35 SR ICM Secondary ICD VR Yes ICD VR No 1, 6 23
15 F 48 I 60 SR LQTS Secondary ICD DR Yes ICD DR No 1, 6 19
16 F 16 I 66 SR LQTS Secondary No No No No 3 18
17 M 45 II 43 SR DCM Primary ICD VR Yes No No 2, 3, 4, 5 18
18 F 38 I 50 SR IVF Secondary ICD VR Yes ICD VR No 1, 3, 6 18
19 F 48 I 62 SR IVF Secondary No No No No 3 15
20 M 13 I 60 SR LQTS Secondary No No No No 3 9
21 F 31 I 60 SR IVF Secondary No No No No 3 7
22 M 51 I 60 SR IVF Secondary ICD VR Yes No No 2, 4, 5 2
23 M 66 II 35 AF ICM Primary No No No No 1, 2 1
24 M 44 III 60 SR ARVC Secondary ICD VR Yes No No 2, 4, 5 1
25 M 58 I 60 SR IVF Secondary No No No No 2 0
a 1 – problematic vascular access; 2 – high risk of infection; 3 – young age; 4 – history of cardiac implantable electronic device infection; 5 – history of infective endocarditis; 6 – prior lead failure and transvenous lead extraction
Abbreviations: AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; AVB, atrioventricular block; CIED, cardiac implantable electronic device; F, female; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter ‑defibrillator; 
ICM, ischemic cardiomyopathy; IVF, idiopathic ventricular fibrillation; LBBB, left bundle branch block; LQTS, long QT syndrome; LVEF, left ventricular ejection fraction; LVNC, left ventricular non compaction; M, male; NICM, non ischemic cardiomyopathy; 
NYHA, New York Heart Association; SCD, sudden cardiac death; S ‑ICD, subcutaneous implantable cardioverter ‑defibrillator; SR, sinus rhythm; TLE, transvenous lead extraction
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threshold.4 Our results seem to confirm that hy‑
pothesis (100% efficacy of the 65‑J impulse).
Surgical complications of S ‑ICD implantation 
were reported to affect between 10% and 20% 
patients in the early years of the method. With 
increasing experience, the percentage of compli‑
cations decreased to 3% in the first postopera‑
tive month.5 In our cohort, we did not observe 
surgical complications in any of the de ‑novo im‑
plantations during the whole follow ‑up.
Inadequate interventions of S ‑ICD during 
the follow ‑up were observed in 5 patients (20%). 
In early‑stage publications, the annual rate of 
inadequate interventions was between 7% and 
13%, and has then been reduced to several per‑
cent due to improved detection and program‑
ming of 2 detection zones.6 In our cohort, the in‑
adequate intervention was caused by AF only in 
2 cases. In the next 2 cases, inadequate thera‑
pies were due to interaction of a S ‑ICD with a co‑
existing pacemaker. In the last case, the cause 
of inadequate interventions could not be deter‑
mined. In that patient, the whole system was re‑
placed. In conclusion, inadequate interventions 
related to supraventricular arrhythmias were ob‑
served in 2 patients (8%), which is in line with 
the rates observed in other studies.
In our cohort, we observed 2 patients with 
a coexisting S ‑ICD and pacemaker. In both cases, 
inadequate interventions of S ‑ICD occurred due 
to the possible interaction between the devices. 
In patient 5, the possible cause of intervention 
was the decreased voltage of R ‑wave with concur‑
rent myopotentials associated with physical ac‑
tivity. Permanent cardiac pacing from the DDD 
pacemaker as the reason for R ‑wave morphology 
change could neither be confirmed nor excluded. 
On repeated screening, none of the 3 electrocar‑
diography vectors registered during pacing were 
appropriate for the use of S ‑ICD. The producer’s 
representative suggested S ‑ICD system replace‑
ment, but with no guarantee that it would solve 
the problem. The decision was made to discontin‑
ue the S ‑ICD use, and the device was switched off.
The second patient requiring permanent car‑
diac pacing (patient 13) also experienced inade‑
quate intervention, despite prior positive screen‑
ing for S ‑ICD. It was caused by T ‑wave oversens‑
ing of the T wave changed in morphology due to 
overlay of P and T waves in the course of first‑
‑degree atrioventricular block. The problem was 
solved with pacemaker reprogramming.
As the S ‑ICD system cannot provide perma‑
nent cardiac pacing, the issue of possible in‑
teractions between a pacemaker and S ‑ICD is 
of paramount importance. Current guidelines 
state that S ‑ICD implantation is contraindicat‑
ed in case of bradycardia requiring cardiac pac‑
ing.1 Nonetheless, it may be expected that indi‑
cations for permanent cardiac pacing may de‑
velop in some patients after the implantation 
of S ‑ICD. In populations of patients with S ‑ICD, 
nature of interventions could not be deter‑
mined. Patient 5 experienced inadequate in‑
terventions twice. The first one occurred dur‑
ing the early postoperative period. The analysis 
of recordings from the device memory (in coop‑
eration with the manufacturer) did not result 
in any conclusive explanation of the nature of 
noise registered by the device.2 The second in‑
adequate intervention occurred in month 36 of 
the follow ‑up. It was due to inappropriate detec‑
tion, most certainly resulting from the R ‑wave 
morphology change during permanent cardi‑
ac pacing delivered by a DDD pacemaker with 
epicardial leads. Repeated automated screen‑
ing for S ‑ICD failed to confirm any possibility 
of appropriate sensing in that patient. As no 
ventricular arrhythmia was recorded during 
the follow ‑up period and the patient present‑
ed substantial improvement in left ventricular 
ejection fraction, a decision was made to switch 
the S ‑ICD device off.
Patient 6 experienced inadequate interven‑
tions 3 times while staying abroad. Due to 
the fact that no explanation for the noise that 
caused those interventions could be found by 
consulting electrophysiologists or manufactur‑
er’s representatives, the whole S ‑ICD system was 
replaced with a new one (new S ‑ICD) in a local 
hospital.
Patient 8 experienced inadequate interven‑
tions due to a sudden 2‑fold increase of the ven‑
tricular rate of permanent AF. As a solution, 
the device settings were modified and rate‑
‑lowering treatment intensified.
Patient 17 had 5 episodes of AF with fast ven‑
tricular rate leading to inadequate interventions, 
and therefore pulmonary vein isolation was per‑
formed with good outcome.
Patient 13 experienced single inadequate 
shock in the postoperative period. The interven‑
tion was due to AAI pacing from the previously 
implanted permanent dual ‑chamber pacemaker 
with a first degree atrioventricular conduction 
block, which resulted in the overlay of paced 
P and T waves, and oversensing of that modi‑
fied T ‑wave by the S ‑ICD. The settings for pac‑
ing of the pacemaker and detection of the S ‑ICD 
were reprogrammed. The problem was never ob‑
served again.
No other inadequate interventions were ob‑
served. Data concerning coexisting devices may 
be found in Supplementary material (Table S2).
The efficacy of S ‑ICD in defibrillation testing 
in clinical studies is estimated at over 90%,3 and 
a need for surgical repositioning can occur in 5% 
of cases. In our population with 21 defibrillation 
tests performed, there was a need for shock po‑
larity reversal only in 1 case (4.7%). In all the re‑
maining cases, an impulse of 65 J proved effec‑
tive. The device can was placed dorsally in re‑
lation to the midaxillary line, and such a loca‑
tion may promote lowering of the defibrillation 
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the absolute indication for pacemaker occurred 
in 2 patients out of 882 during 2 years (0.2%). 
In our cohort, both patients had the pacemak‑
er implanted prior to S ‑ICD qualification, and 
the S ‑ICD system was implanted nonetheless, 
because no other therapeutic option was avail‑
able in those patients. In no other case did we 
observe an indication for pacemaker develop af‑
ter S ‑ICD implantation.
Summary The  authors acknowledge that 
a small study group is the main limitation of 
the above analysis. Nonetheless, the aim of our 
report was to present our single ‑center results 
and troubleshoot specific real ‑life problems. 
A small number of patients with S ‑ICDs in our 
cohort is mainly caused by limited reimburse‑
ment of the system by the National Healthcare 
Fund in Poland. Our results confirm the efficacy 
of the treatment option and low risk of surgical 
complications, which suports its further more 
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